Lessons Learned in Other Cancers and Suggested Endpoints in

Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.

Related Keywords

, Data Updates , Resectable Cutaneous Squamous Cell Carcinoma , Suggested Endpoints , Future Trials , Cutaneous Squamous Cell Carcinoma , Mcscc , Skin Cancer , Squamous Cell Skin Cancer , Trio Therapy , Immune Checkpoint Inhibitors , Neoadjuvant Therapy , Neoadjuvant Treatment , Rectal Cancer , Hnscc , Melanoma , Trial Endpoints , Clinical Trial Endpoints , Clinical Trials ,